Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi

Ersoy, Canan; EREK, Müge; ERSOY, ALPARSLAN

Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi

Müge EREK, (Uludağ Üniversitesi Tıp Fakültesi)

Canan ERSOY, (Uludağ Üniversitesi Tıp Fakültesi)

Alparslan ERSOY (Uludağ Üniversitesi Tıp Fakültesi)

Uludağ Üniversitesi Tıp Fakültesi Dergisi

6 0

Yıl: 2017 Cilt: 43 Sayı: 3 Sayfa Aralığı: 123 - 128 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi

Öz:

Hipertansif tip 2 diyabetli hastalarda losartan tedavisinin tek başına ve silazapril veya karvedilol ile kombinasyonunun kan basıncı, glisemik kontrol, insülin direnci (IR) ve lipid profili üzerine kısa dönem etkinliklerini karşılaştırmayı amaçladık. Çalışma, tip 2 diyabetik ve hipertansif 21 hastada yapıldı. 2 haftalık izlem sonrası (Dönem 1), hastalar 6 hafta süreyle losartan 50 mg/gün aldı (Dönem 2). Sonra 6 hafta süreyle hastalar 3 gruba ayrıldı: losartan 100 mg/gün (Grup 1), losartan 50 mg/gün ve karvedilol 25 mg/gün (Grup 2) veya silazapril 5 mg/gün (Grup 3) (Dönem 3). Losartan tedavisi sonrası ortalama vücut kütle indeksi, kan basıncı, bel ve kalça çevreleri anlamlı azaldı. Dönem 3'te grupların sistolik kan basınçları anlamlı azaldı. Sadece Grup 3'te diyastolik kan basıncındaki azalma anlamlıydı. Grup 1'de vücut kütle indeksi, Grup 1 ve Grup 3'te bel çevreleri, Grup 1'de kalça çevresi anlamlı azaldı. Dönem 1, 2 ve 3'te hastaların açlık ve tokluk glukoz, insülin, HOMA IR, fruktozamin, HbA1c, lipid düzeyleri anlamlı değişmedi. Tip 2 diyabetik hastalarda yüksek doz losartan, losartan+silazapril ve losartan+karvedilol tedavileri kan basıncını düşürdü. Ancak bu rejimler glisemik kontrol, IR ve lipid profilini etkilemedi.

Anahtar Kelime:

Konular: Anestezi Endokrinoloji ve Metabolizma

The Effect of Different Antihypertensive Drug Regimens on Insulin Resistance in Hypertensive Type 2 Diabetic Patients

Öz:

We aimed to compare the short-term efficacies of losartan treatment alone and in combination with cilazapril or carvedilol on blood pressure, glycemic control, insülin resistance (IR) and lipid profile in hypertensive type 2 diabetic patients. The study included 21 type 2 diabetic and hypertensive patients. After 2 weeks follow-up (Period 1), patients received losartan 50 mg/day for 6 weeks (Period 2). Then, patients were divided into 3 groups for 6 weeks: losartan 100 mg/day (Group 1), losartan 50 mg/day and carvedilol 25 mg/day (Group 2) or cilazapril 5 mg/day (Group 3) (Period 3). After losartan treatment, mean body mass index, blood pressure, waist and hip circumferences decreased significantly. Systolic blood pressures decreased in all groups in period 3. Only the decrease in diastolic blood pressure in Group 3 was significant. Body mass index in Group 1, waist circumference in Group 1 and Group 3, and hip circumference in Group 1 significantly decreased. In period 1, 2 and 3, glucose, insulin, HOMA IR, fructosamine, HbA1c and lipid values of the patients did not change significantly. High-dose losartan, losartan+cilazapril and losartan+carvedilol treatments decreased blood pressure in type 2 diabetic patients. However, these regimens did not affect glycemic control, IR and lipid profile.

Anahtar Kelime:

Konular: Anestezi Endokrinoloji ve Metabolizma

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ahmad MA, Kapur P, Khanam R, et al. Comparative effect of antihypertensive therapy on blood glucose level in hypertensive patients in an Indian population. Drug Res (Stuttg) 2014;64:276-80.
2. Katsiki N, Purrello F, Tsioufis C, Mikhailidis DP. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother 2017;18:1243-60.
3. Karagiannis A, Tziomalos K, Anagnostis P, et al. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Pharmacol 2010;8:792-803.
4. Parving HH, Lehnert H, Brochner-Mortensen J, et al. Irbesartan in patients with type 2 diabetes and microalbuminuria Study group. The effect of irbesartan on the development of diabetic Nephropathy in patients with type 2 diabetes. N Engl J Med 2000;345:870-8.
5. Zeeuw D, Remuzzi G, Parving HH et al: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110: 921-7.
6. Hansson L, Lindholm LH, Ekbom T, et al. Randomised Trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor DA, Treacher DF, Turner RC. Homeostasis model assessment: insülin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
9. García-Donaire JA, Segura J, Cerezo C, Ruilope LM. A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Press 2011;20:322-34.
10. UKPDS Group: UK Prospective Diabetes Study 38: tight Blood pressure Control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998:317:703-13.
11. Hansson L, Zanchetti A, Carrthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomized trial. Lancet 1998;351:1755-62.
12. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetics on lbuminuria, retinopathy, and strokes. Kidney Int 2002;61:1086-97.
13. Adler Al, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective obsevational Study. BMJ 2000;321:412-9.
14. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetic cohort of the International Verapamil SRTrandolapril Study. Hypertension 2004;44:643-8.
15. American Diabetes Association: Standarts of medical care in diabetes (Position Statement). Diabetes Care 2005;28:4-36.
16. Heart Outcomes Prevention Evaluation Study Investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
17. On behalf of the EUROPA Investigators: The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA Study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78.
18. ALLHAT Collaborative Research Group: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9.
19. Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol 2006;10:193-200.
20. Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H. Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy irbesartan in Diabetic Nephropathy Trial (IDNT). Dtsch Med Wochenschr 2006;131:1721-6.
21. Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of ınflammatory activity in patients with type 2 diabetes and microalbuminuria: An IRMA 2 Substudy. Diabetes 2006;55:3550-5.
22. Smith DG, Nguyen AB, Peak CN, Frech FH. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. MicroAlbuminuria Reduction With VALsartan (MARVAL) study. J Manag Care Pharm 2004;10:26-32.
23. Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled trial. Diabet Med 2004;21:471-5.
24. Black HR. Evolving role of aldosterone blockers alone and in combination with Angiotensin-converting enzyme inhibitors or Angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. Am Heart J 2004;147:564-72.
25. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90:1765-73.
26. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
27. Swedberg K, Cleland J, Dargie H, et al. Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
28. Himmelmann A, Hansson L, Hansson BG, et al. Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade. Am J Hypertens 1996;9:850-3.
29. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
30. Ruffalo RR, Feurstein GZ. Pharmacology of Carvedilol: Rationale for use in Hypertension, Coronary artery Disease and congestive heart Failure. Cardiovasc Drugs Ther 1997;11:247-56.
31. Albergani F, Paterno E, Venuti RP, et al. Comparison of the effects of carvedilol and nifedipine in patients with essential hipertension and non-insulin-dependent diabetes mellitus. J Cardiovasc Pharmacol 1992;19(suppl 1):86-9.
32. Ruffolo RR, Feuerstein GZ, Ohlstein EH. Recent observations with ß-adrenoceptor blockage: beneficial effects in hypertension and heart failure. Am J Hypertens 1998;11:9-14.
33. Song SH, Brown PM. Coronary heart disease risk assesment in diabetes mellitus. Comparison of UKPDS risk engine with Framingam risk assesment function and its clinical implications. Diabet Med 2004;21:238-45.
34. Colagiuri S, Cull CA, Holman RR. Are lower fasting glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? US Prospective Diabetes Study 61. Diabetes Care 2002;25:1410-7.
35. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-42.
36. Abraham WT, Hensen J, Schrier RW. Elevated plasma noradrenaline concentrations in patients with low-output cardiac failure: dependence on increased noadrenaline secretion rates. Clin Sci (Lond) 1990;79:429-35.
37. Hall JA, Kaumann AJ, Brown MJ. Selective beta 1 adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2 adrenoceptors in human atrial myocardium. Circ Res 1990;66:1610-23.
38. Ahmed A. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. Eur J Heart Fail 2003;5:709-15.
39. Lee IT, Hung YJ, Chen JF, Wang CY, Lee WJ, Sheu WH. Comparison of the efficacy and safety profiles of two fixeddose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2012;34:1735-50.

APA	EREK M, Ersoy C, ERSOY A (2017). Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. , 123 - 128.
Chicago	EREK Müge,Ersoy Canan,ERSOY ALPARSLAN Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. (2017): 123 - 128.
MLA	EREK Müge,Ersoy Canan,ERSOY ALPARSLAN Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. , 2017, ss.123 - 128.
AMA	EREK M,Ersoy C,ERSOY A Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. . 2017; 123 - 128.
Vancouver	EREK M,Ersoy C,ERSOY A Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. . 2017; 123 - 128.
IEEE	EREK M,Ersoy C,ERSOY A "Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi." , ss.123 - 128, 2017.
ISNAD	EREK, Müge vd. "Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi". (2017), 123-128.

APA	EREK M, Ersoy C, ERSOY A (2017). Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 43(3), 123 - 128.
Chicago	EREK Müge,Ersoy Canan,ERSOY ALPARSLAN Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. Uludağ Üniversitesi Tıp Fakültesi Dergisi 43, no.3 (2017): 123 - 128.
MLA	EREK Müge,Ersoy Canan,ERSOY ALPARSLAN Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. Uludağ Üniversitesi Tıp Fakültesi Dergisi, vol.43, no.3, 2017, ss.123 - 128.
AMA	EREK M,Ersoy C,ERSOY A Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2017; 43(3): 123 - 128.
Vancouver	EREK M,Ersoy C,ERSOY A Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2017; 43(3): 123 - 128.
IEEE	EREK M,Ersoy C,ERSOY A "Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi." Uludağ Üniversitesi Tıp Fakültesi Dergisi, 43, ss.123 - 128, 2017.
ISNAD	EREK, Müge vd. "Hipertansif Tip 2 Diyabetik Hastalarda Farklı Antihipertansif İlaç Rejimlerinin İnsülin Direnci Üzerine Etkisi". Uludağ Üniversitesi Tıp Fakültesi Dergisi 43/3 (2017), 123-128.